Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Eun Suk | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Lee, Soon Jae | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Lee, Beom Jae | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Seo, Tae-Seok | - |
dc.contributor.author | Lee, Chang Hee | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Bak, Young Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.accessioned | 2021-09-06T01:02:55Z | - |
dc.date.available | 2021-09-06T01:02:55Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2013-06 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103080 | - |
dc.description.abstract | Background & Aims: Recently, new methods, including the concept of viable enhancing tumor such as EASL and mRECIST, have been proposed for substitution of the conventional WHO and RECIST criteria in hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). Herein, we evaluated the differences of four methods and compared the association of these methods with the prognosis of HCC patients undergoing TACE. Methods: We retrospectively reviewed 114 consecutive newly diagnosed HCC patients who underwent TACE as initial treatment. We evaluated the intermethod agreement (kappa values) between the methods and compared their association with the prognosis of HCC patients. Results: The kappa values for EASL vs. WHO, EASL vs. RECIST, mRECIST vs. WHO, and mRECIST vs. RECIST were low, of 0.102, 0.088, 0.112, and 0.122, respectively. However, good correlations were observed for WHO vs. RECIST and EASL vs. mRECIST (kappa = 0.883, kappa = 0.759, respectively p <0.001). The median OS was 32.3 months. Hazard ratios (HR) for survival in responders compared with non-responders were 0.21 (95% CI; 0.12-0.37, p<0.001) for EASL and 0.27 (95% Cl; 0.15-0.48, p<0.001) for mRECIST. The mean survival of responders was significantly longer than that of non-responders in both EASL (40.8 vs. 16.9 months, p<0.001) and mRECIST (41.1 vs. 20.7 months, p<0.001). In multivariate analysis, EASL response (HR 0.21, 95% CI 0.11-0.40, p<0.001) and mRECIST response (HR; 0.31, 95% CI, 0.17-0.59, p<0.001) were independently associated with survival. Conclusions: The response assessment by EASL and mRECIST could reliably predict the survival of HCC patients undergoing TACE and could be applicable in practice in preference to the conventional WHO and RECIST criteria. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | RANDOMIZED CONTROLLED TRIAL | - |
dc.subject | SOLID TUMORS | - |
dc.subject | EVALUATION CRITERIA | - |
dc.subject | END-POINTS | - |
dc.subject | CANCER | - |
dc.subject | EMBOLIZATION | - |
dc.subject | MANAGEMENT | - |
dc.subject | AGREEMENT | - |
dc.subject | SURVIVAL | - |
dc.subject | EASL | - |
dc.title | Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Beom Jae | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Seo, Tae-Seok | - |
dc.contributor.affiliatedAuthor | Lee, Chang Hee | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Park, Jong-Jae | - |
dc.contributor.affiliatedAuthor | Bak, Young Tae | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.1016/j.jhep.2013.01.039 | - |
dc.identifier.scopusid | 2-s2.0-84877920514 | - |
dc.identifier.wosid | 000318960700018 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATOLOGY, v.58, no.6, pp.1181 - 1187 | - |
dc.relation.isPartOf | JOURNAL OF HEPATOLOGY | - |
dc.citation.title | JOURNAL OF HEPATOLOGY | - |
dc.citation.volume | 58 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1181 | - |
dc.citation.endPage | 1187 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED TRIAL | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | EVALUATION CRITERIA | - |
dc.subject.keywordPlus | END-POINTS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | EMBOLIZATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | AGREEMENT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EASL | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Response | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Transarterial chemoembolization | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.